|
1
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in Untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
Non-Small-Cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Busch W: Einfluβ von Erysipel. Berliner
Klin Wschr. 3:245–246. 1866.(In German).
|
|
6
|
Maruyama C: On the treatment of malignant
tumor with an extract from tubercle bacilli. Jpn J Dermatol.
76:399–404. 1966.(In Japanese).
|
|
7
|
Tsung K and Norton JA: Lessons from
Coley's Toxin. Surg Oncol. 15:25–28. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kobatake H, Suekane T, Murakami Y, Niwa S,
Okahira A and Kushida H: Studies on hot water extract of
Mycobacterium tuberculosis. I. Structural analyses of
polysaccharides (author's transl). Yakugaku Zasshi. 101:713–722.
1981.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
9
|
Oka H, Shiraishi Y, Sasaki H, Yoshinaga K,
Emori Y and Takei M: Antimetastatic effect of an immunomodulatory
arabinomannan extracted from Mycobacterium tuberculosis strain
Aoyama B, Z-100, through the production of interleukin-12. Biol
Pharm Bull. 26:1336–1341. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Oka H, Emori Y, Sasaki H, Shiraishi Y,
Yoshinaga K and Kurimoto T: Anti-tumor mechanism of Z-100, an
immunomodulatory Arabinomannan extracted from Mycobacterium
tuberculosis strain Aoyama B, on pulmonary metastases of B16F10
melanoma: Restoration of helper T cell responses via suppression of
glucocorticoid-genesis. Microbiol Immunol. 46:343–351.
2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Oka H, Sasaki H, Shiraishi Y, Emori Y,
Yoshinaga K and Takei M: Z-100, an immunomodulatory arabinomannan
extracted from Mycobacterium tuberculosis strain Aoyama B, augments
anti-tumor activities of X-ray irradiation against B16 melanoma in
association with the improvement of type 1 T cell responses. Biol
Pharm Bull. 27:82–88. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mitsuishi T, Kabashima K, Tanizaki H,
Ohsawa I, Oda F, Yamada Y, Halifu Y, Kawana S, Kato T and Iida K:
Specific substance of Maruyama (SSM) suppresses immune responses in
atopic dermatitis-like skin lesions in DS-Nh mice by modulating
dendritic cell functions. J Dermatol Sci. 63:184–190.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kobayashi K, Kaira K and Kagamu H:
Recovery of the sensitivity to Anti-PD-1 antibody by celecoxib in
lung cancer. Anticancer Res. 40:5309–5311. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Murphy K and Weaver C: Chapters: 3-5. In:
Janeway's Immunobiology. 9th edition. W.W. Norton & Company,
Inc., New York, 2017.
|
|
15
|
Shah RR, Hassett KJ and Brito LA: Overview
of vaccine adjuvants: Introduction, history, and current status.
Methods Mol Biol. 1494:1–13. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Reed SG, Orr MT and Fox CB: Key roles of
adjuvants in modern vaccines. Nat Med. 19:1597–608. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Hsu PC, Jablons DM, Yang CT and You L:
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated
Protein (YAP) and the Regulation of Programmed Death-Ligand 1
(PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int J Mol Sci.
20(E3821)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Reits EA, Hodge JW, Herberts CA, Groothuis
TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH,
Neijssen J, et al: Radiation modulates the peptide repertoire,
enhances MHC class I expression, and induces successful antitumor
immunotherapy. J Exp Med. 203:1259–1271. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Formenti SC, Rudqvist NP, Golden E, Cooper
B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari
de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces
responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sugiyama T, Fujiwara K, Ohashi Y, Yokota
H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K and Noda K:
Phase III placebo-controlled double-blind randomized trial of
radiotherapy for stage IIB-IVA cervical cancer with or without
immunomodulator Z-100: A JGOG study. Ann Oncol. 25:1011–1017.
2014.PubMed/NCBI View Article : Google Scholar
|
